Equities research analysts expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to post ($0.57) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Syros Pharmaceuticals’ earnings, with estimates ranging from ($0.60) to ($0.56). Syros Pharmaceuticals posted earnings per share of ($0.47) in the same quarter last year, which would indicate a negative year over year growth rate of 21.3%. The business is scheduled to issue its next quarterly earnings report on Monday, March 19th.
On average, analysts expect that Syros Pharmaceuticals will report full year earnings of ($2.12) per share for the current year, with EPS estimates ranging from ($2.14) to ($2.10). For the next financial year, analysts forecast that the company will post earnings of ($2.60) per share, with EPS estimates ranging from ($3.69) to ($2.00). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Syros Pharmaceuticals.
A number of equities analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. HC Wainwright reaffirmed a “hold” rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a report on Thursday, December 21st. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Syros Pharmaceuticals in a report on Tuesday, October 31st. Oppenheimer set a $28.00 price objective on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, January 8th. Finally, Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a report on Monday, December 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $22.36.
Syros Pharmaceuticals (NASDAQ:SYRS) traded down $0.21 on Thursday, reaching $9.97. 103,945 shares of the company’s stock were exchanged, compared to its average volume of 307,756. The stock has a market cap of $262.18 and a P/E ratio of -5.73. Syros Pharmaceuticals has a 1 year low of $6.30 and a 1 year high of $24.38.
In related news, Director Srinivas Akkaraju purchased 109,774 shares of the business’s stock in a transaction that occurred on Thursday, December 14th. The shares were bought at an average cost of $9.03 per share, with a total value of $991,259.22. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jeremy P. Springhorn purchased 15,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average cost of $9.08 per share, for a total transaction of $136,200.00. The disclosure for this purchase can be found here. Insiders purchased a total of 334,198 shares of company stock worth $3,127,458 over the last three months. 33.60% of the stock is owned by insiders.
Several large investors have recently modified their holdings of SYRS. Two Sigma Advisers LP purchased a new position in shares of Syros Pharmaceuticals in the 4th quarter worth about $105,000. Adalta Capital Management LLC purchased a new position in shares of Syros Pharmaceuticals in the 4th quarter worth about $111,000. Nationwide Fund Advisors boosted its holdings in shares of Syros Pharmaceuticals by 249.8% in the 2nd quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after buying an additional 5,016 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Syros Pharmaceuticals in the 3rd quarter worth about $133,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Syros Pharmaceuticals in the 3rd quarter worth about $149,000. 48.81% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/22/0-57-earnings-per-share-expected-for-syros-pharmaceuticals-inc-syrs-this-quarter.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.